References
- Kurd M, Sadegh Malvajerd S, Rezaee S, et al. Oral delivery of indinavir using mPEG-PCL nanoparticles: preparation, optimization, cellular uptake, transport and pharmacokinetic evaluation. Artif Cells Nanomed Biotechnol. 2019;47(1):2123–2133.
- Lewthwaite P, Wilkins E. Natural history of HIV/AIDS. Medicine (Baltimore). 2009;7(7):333–337.
- HIV/AIDS [Internet]. cited 2021 Oct 29]. Available from 2021 Oct 29: https://www.who.int/news-room/fact-sheets/detail/hiv-aids.
- Pau AK, George JM. Antiretroviral therapy: current drugs. Infect Dis Clin North Am. 2014;28(3):371–402.
- Moyle GJ, Gazzard BG, Cooper DA, et al. Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use. Drugs. 1998;55(3):383–404.
- Lv Z, Chu Y, Wang Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl). 2015;7:95–104.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. [cited 2022 May 24]. [Internet]. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf.
- TRIUMEQ. [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205551s000lbl.pdf
- TRIUMEQ PD [Internet]. cited 2022 May 20] Available from 2022 May 20: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG-IFU.PDF
- TRIZIVIR. [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021205s036lbl.pdf
- EVOTAZ. [cited 2022 May 20]. [Internet]. Available from: https://packageinserts.bms.com/pi/pi_evotaz.pdf
- BIKTARVY. [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf.
- CABENUVA [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212888s000lbl.pdf
- PREZCOBIX [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205395s018lbl.pdf
- SYMTUZA [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210455s000lbl.pdf.
- DOVATO [Internet]. cited 2022 May 20] Available from 2022 May 20: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211994s000lbl.pdf.
- JULUCA [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210192s000lbl.pdf.
- DELSTRIGO [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210807s003lbl.pdf.
- SYMFI LO [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208255s000lbl.pdf.
- GENVOYA [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207561s000lbl.pdf.
- STRIBILD. [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203100s030lbl.pdf
- ODEFSEY [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208351s000lbl.pdf
- COMPLERA [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202123s003lbl.pdf
- DESCOVY [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208215s012lbl.pdf
- TRUVADA [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.gilead.com/~/media/Files/pdfs/medicines/hiv/truvada/truvada_pi.pdf
- CIMDUO [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022141s000lbl.pdf
- PIFELTRO [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf
- INTELENCE [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022187s009lbl.pdf
- VIRAMUNE XR [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201152s002lbl.pdf
- EDURANT [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202022s013lbl.pdf.
- VOCABRIA [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212887s000lbl.pdf.
- TIVICAY [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf
- ISENTRESS [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf
- RUKOBIA [Internet]. cited 2022 May 20] Available from 2022 May 20: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Rukobia/pdf/RUKOBIA-PI-PIL.PDF.
- TROGARZO [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761065lbl.pdf
- TYBOST [Internet]. cited 2022 May 20] Available from 2022 May 20: https://www.gilead.com/~/media/Files/pdfs/medicines/hiv/tybost/tybost_pi.pdf
- Alvi RM, Neilan AM, Tariq N, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV and heart failure. J Am Coll Cardiol. 2018;72(5):518–530.
- Ansari H, Singh P. Formulation and in-vivo evaluation of novel topical gel of Lopinavir for targeting HIV. Curr HIV Res. 2018;16(4):270–279.
- Freeling JP, Koehn J, Shu C, et al. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. AIDS Res Hum Retroviruses. 2015;31(1):107–114.
- Kigen G, Edwards G. Enhancement of saquinavir absorption and accumulation through the formation of solid drug nanoparticles. BMC Pharmacol Toxicol. 2018;19(1):79.
- He Y, Xia D, Li Q, et al. Enhancement of cellular uptake, transport and oral absorption of protease inhibitor saquinavir by nanocrystal formulation. Acta Pharmacol Sin. 2015;36(9):1151–1160.
- Mahajan SD, Roy I, Xu G, et al. Enhancing the Delivery of Anti Retroviral drug “Saquinavir” across the blood brain barrier using nanoparticles. Curr HIV Res. 2010;8(5):396–404.
- Desai J, Thakkar H. Darunavir-loaded lipid nanoparticles for targeting to HIV reservoirs. AAPS PharmSciTech. 2018;19(2):648–660.
- Desai J, Thakkar H. Enhanced oral bioavailability and brain uptake of Darunavir using lipid nanoemulsion formulation. Colloids Surf B Biointerfaces. 2019;175:143–149.
- Karami Z, Saghatchi Zanjani MR, Rezaee S, et al. Neuropharmacokinetic evaluation of lactoferrin-treated indinavir-loaded nanoemulsions: remarkable brain delivery enhancement. Drug Dev Ind Pharm. 2019;45(5):736–744.
- Belubbi T, Shevade S, Dhawan V, et al. Lipid architectonics for superior oral bioavailability of nelfinavir mesylate: comparative in vitro and in vivo assessment. AAPS PharmSciTech. 2018;19(8):3584–3598.
- Ravi PR, Vats R, Dalal V, et al. A hybrid design to optimize preparation of Lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation. J Pharm Pharmacol. 2014;66(7):912–926.
- (FDA approved drug products: NORVIR (Ritonavir) capsules, soft gelatin for oral use - google search [Internet]. cited 2021 Oct 29]. Available from 2021 Oct 29: https://www.google.com/search?q=%28FDA+Approved+Drug+Products%3A+NORVIR+%28ritonavir%29+Capsules%2C+Soft+Gelatin+for+Oral+use&rlz=1C1YTUH_enIN969IN969&sxsrf=AOaemvIGAKL8SNdpbURMSATS6lRqXjX34A%3A1635515433925&ei=Kfx7YZj3N4O_8QPw2ZOYBw&oq=%28FDA+Approved+Drug+Products%3A+NORVIR+%28ritonavir%29+Capsules%2C+Soft+Gelatin+for+Oral+use&gs_lcp=Cgdnd3Mtd2l6EAwyBwgjELADECcyBwgAEEcQsAMyBwgAEEcQsAMyBwgAEEcQsAMyBwgAEEcQsAMyBwgAEEcQsAMyBwgAEEcQsAMyBwgAEEcQsAMyBwgAEEcQsANKBAhBGABQAFgAYMVEaAJwAngAgAEAiAEAkgEAmAEAyAEJwAEB&sclient=gws-wiz&ved=0ahUKEwjYr9rj4e_zAhWDX3wKHfDsBHMQ4dUDCA4.
- Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A. 1995;92(7):2484–2488.
- Martin P, Giardiello M, McDonald TO, et al. Augmented inhibition of CYP3A4 in human primary hepatocytes by ritonavir solid drug nanoparticles. Mol Pharm. 2015;12(10):3556–3568.
- Xu H, Krakow S, Shi Y, et al. In vitro characterization of ritonavir formulations and correlation to in vivo performance in dogs. Eur J Pharm Sci. 2018;115:286–295.
- De Espíndola B, Beringhs AO, Sonaglio D, et al. Liquisolid pellets: a pharmaceutical technology strategy to improve the dissolution rate of Ritonavir. Saudi Pharm J. 2019;27(5):702–712.
- Mehta C, Narayan R, Aithal G, et al. Molecular simulation driven experiment for formulation of fixed dose combination of darunavir and Ritonavir as anti-HIV nanosuspension. J Mol Liq. 2019;293:111469.
- Chukka S, Shaik S. Development and characterization of gastroretentive drug delivery system for ritonavir tablets using natural polymers. Asian J Pharm Clin Res. 2017;10(5):318–322.
- norvir-epar-scientific-disc -Google Search [Internet]. cited 2021 Oct 29]. Available from 2021 Oct 29: https://www.google.com/search?q=norvir-epar-scientific-disc&rlz=1C1YTUH_enIN969IN969&oq=norvir-epar-scientific-disc&aqs=chrome.69i57j69i60.1598j0j7&sourceid=chrome&ie=UTF-8.
- Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, Ritonavir and saquinavir. Clin Pharmacol Ther. 1998;63(4):453–464.
- Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, Ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997;44(2):190–194.
- Markowitz M, Saag M, Powderly WG, et al. A preliminary study of Ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995;333(23):1534–1539.
- Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of Ritonavir, an inhibitor of HIV-1 protease. European-Australian collaborative Ritonavir study group. N Engl J Med. 1995;333(23):1528–1533.
- Bachmeyer C, Blum L, Cordier F, et al. Early ritonavir-induced maculopapular eruption. Dermatology. 1997;195(3):301–302.
- Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS. 1997;11(7):938–939.
- Mirete G, Masiá M, Gutiérrez F, et al. Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS. Eur J Clin Microbiol Infect Dis. 1998;17(11):810–811.
- Kuang -C-C, Wang Y, P-C H, et al., Ritonavir-induced hepatotoxicity and ultrastructural changes of hepatocytes. Ultrastruct Pathol. 2014;38(5):329–334.
- Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis. 2003;23:183–194. •• The article explains the incidence of hepatotoxicity in clinical subjects after treating with ritonavir.
- Zhong D, Lu X, Conklin BS, et al. HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol. 2002;22(10):1560–1566.
- Périard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. the Swiss HIV cohort study. Circulation. 1999;100(7):700–705.
- Purnell JQ, Zambon A, Knopp RH, et al. Effect of Ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 2000;14(1):51–57.
- Fu W, Chai H, Yao Q, et al. Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression. J Acquir Immune Defic Syndr. 2005;39(2):152–158.
- Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 2005;6(6):421–425.
- Wolfram J, Zhu M, Yang Y, et al. safety of nanoparticles in medicine. Curr Drug Targets. 2015;16(14):1671–1681.
- Sinha S, Ali M, Baboota S, et al. Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug Ritonavir. AAPS PharmSciTech. 2010;11(2):518–527.
- Dhore PW, Dave VS, Saoji SD, et al. enhancement of the aqueous solubility and permeability of a poorly water soluble drug ritonavir via lyophilized milk-based solid dispersions. Pharm Dev Technol. 2017;22(1):90–102.
- Law D, Schmitt EA, Marsh KC, et al. Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations. J Pharm Sci. 2004;93(3):563–570.
- Deshmukh A, Kulkarni S. Solid self-microemulsifying drug delivery system of Ritonavir. Drug Dev Ind Pharm. 2014;40(4):477–487.
- Kumar S, Narayan R, Ahammed V, et al. development of ritonavir solid lipid nanoparticles by box behnken design for intestinal lymphatic targeting. J Drug Delivery Sci Technol. 2018;44:181–189.
- Jitta SR, Bhaskaran NA, Salwa, et al. Anti-oxidant containing nanostructured lipid carriers of Ritonavir: development. Optimization, and in Vitro and in Vivo Evaluations. AAPS Pharm Sci Tech. 2022;23:88. •• The article discusses the preparation, in vitro, and in vivo evaluations of ritonavirvivo evaluations of ritonavirloaded NLCs
- Zielińska A, Carreiró F, Oliveira AM, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules. 2020;25(16):3731.
- Patil PS, Dhawale SC. Development of Ritonavir loaded nanoparticles: in vitro and in vivo characterization. Asian J Pharm Clin Res. 2018;11(3):284–288.
- Giaretta M, Bianchin MD, Kanis LA, et al. Development of innovative polymer-based matricial nanostructures for ritonavir oral administration. J Nanomater. 2019;2019:e8619819.
- Grewal TK, Majeed S, Sharma S. Synthesis and characterization of Poly-(lactide-co-glycolide) nanoparticles encapsulating Zidovudine, Didanosine and Ritonavir. Cnanom. 2018;8(2):135–146.
- van ′t Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of Rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother. 2010;54(5):2042–2050.
- Flexner C, Owen A, Siccardi M, et al. Long-acting drugs and formulations for the treatment and prevention of HIV infection. Int J Antimicrob Agents. 2021;57(1):106220.
- Banoub MG, Bade AN, Lin Z, et al. Synthesis and characterization of long-acting Darunavir prodrugs. Mol Pharm. 2020;17(1):155–166.
- Sudhakar B, Krishna MC, Murthy KVR. Factorial design studies of antiretroviral drug-loaded stealth liposomal injectable: pEGylation, lyophilization and pharmacokinetic studies. Appl Nanosci. 2016;6(1):43–60.
- Dash PK, Gendelman HE, Roy U, et al. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS. 2012;26(17):2135–2144.
- Gautam N, Roy U, Balkundi S, et al. Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob Agents Chemother. 2013;57(7):3110–3120.
- Puligujja P, Balkundi SS, Kendrick LM, et al. Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials. 2015;41:141–150.
- Carbone C, Leonardi A, Cupri S, et al. Pharmaceutical and biomedical applications of lipid-based nanocarriers. Pharm Pat Anal. 2014;3(2):199–215.
- Chaudhary S, Garg T, Murthy RSR, et al., Recent approaches of lipid-based delivery system for lymphatic targeting via oral route. J Drug Target. 2014;22(10):871–882.
- Xia D, He Y, Li Q, et al. Transport mechanism of lipid covered saquinavir pure drug nanoparticles in intestinal epithelium. J Control Release. 2018;269:159–170.
- García-Pinel B, Porras-Alcalá C, Ortega-Rodríguez A, et al. Lipid-Based nanoparticles: application and recent advances in cancer treatment. Nanomaterials (Basel). 2019;9(4):638.
- Javan F, Vatanara A, Azadmanesh K, et al. Encapsulation of Ritonavir in solid lipid nanoparticles: in-vitro anti-HIV-1 activity using lentiviral particles. J Pharm Pharmacol. 2017;69(8):1002–1009.
- Kumar S, Narayan R, Ahammed V, et al. Development of ritonavir solid lipid nanoparticles by box behnken design for intestinal lymphatic targeting. J Drug Delivery Sci Technol. 2018;44:181–189.
- Walimbe CA, More SS, Walawalkar RU, et al. Optimisation of nanostructured lipid carriers of Ritonavir. Inventi Rapid: NDDS . 2012;2012(4): 1–8.
- Gurumukhi VC, Bari SB, Development of ritonavir-loaded nanostructured lipid carriers employing quality by design (QbD) as a tool: characterizations, permeability, and bioavailability studies. Drug Deliv Transl Res. 2022;12(7): 1753–1773.
- Diniz IMA, Chen C, Xu X, et al. Pluronic F-127 hydrogel as a promising scaffold for encapsulation of dental-derived mesenchymal stem cells. J Mater Sci Mater Med. 2015;26(3):153.
- Cao S, Jiang Y, Zhang H, et al. Core-shell nanoparticles for targeted and combination antiretroviral activity in gut-homing T cells. Nanomedicine. 2018;14(7):2143–2153.
- Ravi PR, Vats R. Comparative pharmacokinetic evaluation of Lopinavir and lopinavir-loaded solid lipid nanoparticles in hepatic impaired rat model. J Pharm Pharmacol. 2017;69(7):823–833.
- Churchill M, Nath A. Where does HIV hide? A focus on the central nervous system. Curr Opin HIV AIDS. 2013;8(3):165–169.
- Tang X, Liang Y, Liu X, et al. PLGA-PEG nanoparticles coated with anti-CD45RO and loaded with HDAC plus protease inhibitors activate latent HIV and inhibit viral spread. Nanoscale Res Lett. 2015;10(1):413.
- Mulam TR, Kshirsagar SJ, Kakad SP, et al. formulation and optimization of Ritonavir nasal nanosuspension for brain targeting. Ind Dru. 2021;58(4):28–41.
- Sachdeva YP, Bose P Processes for the preparation of stable polymorphic form I of Ritonavir [Internet]. 2008 cited 2021 Oct 29]. Available from 2021 Oct 29: https://patents.google.com/patent/US20080312300/en?oq=Processes+for+the+Preparation+of+Stable+Polymorphic+Form+I+of+Ritonavir.+U.S.+Patent+Application+11%2f916%2c158.
- Sharma MK, Khanduri CH, Singh PK, et al. Process for the preparation of form I and form II of Ritonavir [Internet]. 2010 cited 2021 Oct 29]. Available from 2021 Oct 29: https://patents.google.com/patent/US20100099885/en?oq=Process+for+the+preparation+of+form+i+and+form+ii+of+ritonavir.+U.S.+Patent+Application+12%2f443%2c749.
- Acquasaliente M, Houllemare D, Zhang G, et al. Ritonavir bis-hydrochloride [Internet]. 2013 cited 2021 Oct 29]. Available from 2021 Oct 29: https://patents.google.com/patent/US8598216B1/en.
- Morissette SL, Almarsson O, Soukasene S Solvates and polymorphs of Ritonavir and methods of making and using the same [Internet]. 2007 cited 2021 Oct 29]. Available from 2021 Oct 29: https://patents.google.com/patent/US7205413B2/en.
- Vellanki SRP, Nadella MM, Mulamalla RR, et al. Improved process for the preparation of Ritonavir [Internet]. 2015 cited 2021 Oct 29]. Available from 2021 Oct 29: https://patents.google.com/patent/WO2015125082A1/en.
- Tiwari R, Agarwal R, Kailya JR, et al. A process for the preparation of solid dispersion of Lopinavir and Ritonavir [Internet]. 2013 cited 2021 Oct 29]. Available from 2021 Oct 29: https://patents.google.com/patent/WO2013080148A1/en.
- Meergans D, Holfinger K Dosage form comprising Lopinavir and Ritonavir [Internet]. 2016 cited 2021 Oct 29]. Available from 2021 Oct 29: https://patents.google.com/patent/US9370578B2/en.
- McDermott TS, Mayer PT, Collman BM, et al. Tablet Dosage Forms [Internet]. 2014 cited 2021 Oct 29]. Available from 2021 Oct 29: https://patents.google.com/patent/US20140234415A1/en?oq=+Tablet+Dosage+Forms.+U.S.+Patent+Application+14%2f184%2c239.
- Pacheco O, Rusoo E, Russo V Soluble, stable and concentrated pharmaceutical composition compromising Ritonavir and process for preparing thereof [Internet]. 2009 cited 2021 Oct 29]. Available from 2021 Oct 29: https://patents.google.com/patent/US7632853B2/en.
- Gosselin P, Betancourt A Pharmaceutical compositions comprising lonafarnib and ritonavir [Internet]. 2016 cited 2021 Oct 29]. Available from 2021 Oct 29: https://patents.google.com/patent/WO2016172342A1/en?oq=Pharmaceutical+compositions+comprising+lonafarnib+and+ritonavir.
- Rosenberg J, Reinhold U, Liepold B, et al. Solid pharmaceutical dosage form comprising a ritonavir and lopinavir solid dispersion [Internet]. 2010 cited 2021 Oct 29]. Available from 2021 Oct 29: https://patents.google.com/patent/EP2258344A2/en